Kyowa Kirin links with Ultragenyx for first-in-class XLH therapy
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).
You may also be interested in...
Kyowa Kirin’s North America Expansion Progresses With Crysvita Commercial Takeover
The Japanese pharma has taken over commercialization of the rare disease drug from Ultragenyx under a planned transition and as part of a broader growth strategy in North America.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.